07:30 AM EDT, 07/17/2025 (MT Newswires) -- I-Mab ( IMAB ) said Thursday it has agreed to buy Bridge Health Biotech for an upfront payment of $1.8 million, plus $1.2 million in non-contingent payments through 2027.

Bridge Health Biotech shareholders may also be entitled to future milestone payments of up to about $3.9 million, I-Mab ( IMAB ) said.

The deal, which will likely be completed in Q3, gives I-Mab ( IMAB ) upstream rights to the CLDN18.2 parental antibody for use in bispecific and multi-specific applications, the company added.